Cited 0 times in
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.